Clinical trials
catalyst calendar across sponsors →Studies where GENB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 5 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, Squarepoint Ops LLC, MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 15.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)NCT07359846To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled asthma.Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: GB-0895, Placebo | Severe Asthma | 786 | Jan 2029 | ≤ 896 d | 2026-08-17 |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)NCT07276724To evaluate the annualized asthma exacerbation rate (AAER) in adult and adolescent subjects with severe uncontrolled asthma.Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: GB-0895, Placebo | Severe Asthma | 786 | Dec 2028 | ≤ 865 d | 2026-08-17 |
| Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerNCT07484022Incidence of AEs and SAEsOpen-label · Treatment | Phase 1 | Recruiting | Drug: GB-4362, enfortumab vedotin (EV), Pembrolizumab | Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 37 | Jun 2027 | ≤ 315 d | 2026-06-18 |
| A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPDNCT07116889Number of participants with treatment related adverse events as assessed by CTCAE 5.0Randomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Biological: GB-0895 (SC), GB-0895 (SC) · Drug: Placebo (SC), Placebo (SC) | Asthma, COPD (Chronic Obstructive Pulmonary Disease) | 156 | May 2027 | ≤ 285 d | 2025-11-05 |
| Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult ParticipantsNCT06920693Composite Outcome: To assess the safety and tolerability of single doses of GB-7624 administered subcutaneously (SC) in healthy volunteers.Randomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Drug: GB-7624, Placebo | Atopic Dermatitis (AD) | 40 | 2026-08-30 | in 11 d | 2025-12-05 |
| Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult ParticipantsNCT07050511To assess the safety and tolerability of a single ascending dose of GB-0669 administered intravenously in healthy volunteersNon-randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: GB-0669, Placebo | SARS CoV-2 | 51 | 2024-11-22actual | — | 2025-07-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19